Overview

Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects

Status:
Completed
Trial end date:
2021-01-06
Target enrollment:
Participant gender:
Summary
The study was conducted toinvestigate whether the bioavailability of 3 mg Glimepiride Tablet Manufactured by PT. Harsen Laboratories was bioequivalent to the reference product, 3 mg Amaryl® Tablet Manufactured by PT. Aventis Indonesia Pharma, Indonesia.
Phase:
N/A
Details
Lead Sponsor:
PT Harsen Laboratories
Collaborator:
PT Pharma Metric Labs
Treatments:
Glimepiride